NEW YORK (GenomeWeb News) – Novartis has signed a definitive agreement to acquire personalized diagnostics lab services firm Genoptix for approximately $470 million.
Novartis will pay $25 per share in cash for all of the outstanding shares of the Carlsbad, Calif.-based company. The purchase price represents an approximately 27 percent premium to Genoptix's Friday closing price on the Nasdaq of $19.76.